Considerations for the conduct of clinical trials with antiinflammatory agents in cystic fibrosis: A cystic fibrosis foundation workshop report

Annals of the American Thoracic Society

Volumn 12, Issue 9, 2015, Pages 1398-1406

  Torphy, Theodore J ^a   Allen, Janet ^b   Cantin, André M ^c   Konstan, Michael W ^d   Accurso, Frank J ^e   Joseloff, Elizabeth ^a   Ratjen, Felix A ^f   Chmiel, James F ^d  

^a CYSTIC FIBROSIS FOUNDATION   (United States)

^b CYSTIC FIBROSIS TRUST   (United Kingdom)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Airway inflammation; Antiinflammatory drugs; Clinical trials; Cystic fibrosis; Lung

Indexed keywords

ANTIINFLAMMATORY AGENT; CANNABINOID 2 RECEPTOR AGONIST; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IXEKIZUMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXIN; PHOSPHODIESTERASE INHIBITOR; RESOLVIN; SECUKINUMAB; UNCLASSIFIED DRUG; CFTR PROTEIN, HUMAN;

APOPTOSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE ACTIVATION; LUNG FUNCTION; MUCOSAL IMMUNITY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RISK ASSESSMENT; STUDY DESIGN; TH17 CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL (TOPIC); FEMALE; GENETICS; LUNG; MUTATION; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HUMANS; LUNG; MUTATION; NEUTROPHILS;

EID: 84942259351     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201506-361OT     Document Type: Conference Paper

References (72)

1. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187: 680-689.
2. Nichols DP, Konstan MW, Chmiel JF. Anti-inflammatory therapies for cystic fibrosis-related lung disease. Clin Rev Allergy Immunol 2008; 35: 135-153.
3. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.
4. Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med 2015; 372: 351-362.
5. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999; 160: 186-191.
6. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150: 448-454.
7. Suter S, Schaad UB, Tegner H, Ohlsson K, Desgrandchamps D, Waldvogel FA. Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: Effect of antimicrobial treatment against Pseudomonas aeruginosa. J Infect Dis 1986; 153: 902-909.
8. Bartlett JA, McCray PB Jr. Cystic fibrosis and defective airway innate immunity. In: Hiemstra PS, Zaat SAJ, editors. Antimicrobial peptides and innate immunity. Basel: Springer Basel; 2013. pp. 275-306.
9. Ratner D, Mueller C. Immune responses in cystic fibrosis: Are they intrinsically defective? Am J Respir Cell Mol Biol 2012; 46: 715-722.
10. Berkebile AR, McCray PB Jr. Effects of airway surface liquid pH on host defense in cystic fibrosis. Int J Biochem Cell Biol 2014; 52: 124-129.
11. Döring G, Albus A, Høiby N. Immunologic aspects of cystic fibrosis. Chest 1988; 94: 109S-115S.
12. Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M, Krauss-Etschmann S, Koller B, Reinhardt D, Roscher AA, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007; 13: 1423-1430.
13. Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, Dunn CE, Davies ZA, Herzenberg LA, Herzenberg LA. Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc Natl Acad Sci USA 2008; 105: 4335-4339.
14. Watt AP, Courtney J, Moore J, Ennis M, Elborn JS. Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax 2005; 60: 659-664.
15. Mayer ML, Blohmke CJ, Falsafi R, Fjell CD, Madera L, Turvey SE, Hancock RE. Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells. J Immunol 2013; 190: 1227-1238.
16. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23: 5-27.
17. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, et al.; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014; 190: 175-184.
18. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, Weed DA, Gelrud A, Regan MM, Laposata M, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350: 560-569.
19. Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 2006; 6: 414-420.
20. Haworth O, Buckley CD. Resolving the problem of persistence in the switch from acute to chronic inflammation. Proc Natl Acad Sci USA 2007; 104: 20647-20648.
21. Torphy TJ. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-370.
22. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481-511.
23. Spina D. PDE4 inhibitors: Current status. Br J Pharmacol 2008; 155: 308-315.
24. Sousa LP, Lopes F, Silva DM, Tavares LP, Vieira AT, Rezende BM, Carmo AF, Russo RC, Garcia CC, Bonjardim CA, et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaBindependent manner. J Leukoc Biol 2010; 87: 895-904.
25. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbröker D, Bethke TD, Hiemstra PS, Rabe KF. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081-1087.
26. Beghè B, Rabe KF, Fabbri LM. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med 2013; 188: 271-278.
27. Schett G, Sloan VS, Stevens RM, Schafer P. Apremilast: A novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis 2010; 2: 271-278.
28. Profita M, Chiappara G, Mirabella F, Di Giorgi R, Chimenti L, Costanzo G, Riccobono L, Bellia V, Bousquet J, Vignola AM. Effect of cilomilast (Ariflo) on TNF-A, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003; 58: 573-579.
29. Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, de Kam ML, Burggraaf J, Cohen AF, Cazzola M, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: Findings from four clinical trials. Lancet Respir Med 2013; 1: 714-727.
30. Parkinson JF. Lipoxin and synthetic lipoxin analogs: An overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets 2006; 5: 91-106.
31. McMahon B, Godson C. Lipoxins: Endogenous regulators of inflammation. Am J Physiol Renal Physiol 2004; 286: F189-F201.
32. Maderna P, Godson C. Taking insult from injury: Lipoxins and lipoxin receptor agonists and phagocytosis of apoptotic cells. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 179-187.
33. Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, Yang R, Uddin J, Guggino WB, Atabani SF, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004; 5: 388-392.
34. Ringholz FC, Buchanan PJ, Clarke DT, Millar RG, McDermott M, Linnane B, Harvey BJ, McNally P, Urbach V. Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis. Eur Respir J 2014; 44: 394-404.
35. Corminboeuf O, Leroy X. FPR2/ALXR agonists and the resolution of inflammation. J Med Chem 2015; 58: 537-559.
36. Maderna P, Godson C. Lipoxins: Resolutionary road. Br J Pharmacol 2009; 158: 947-959.
37. Uddin M, Levy BD. Resolvins: Natural agonists for resolution of pulmonary inflammation. Prog Lipid Res 2011; 50: 75-88.
38. Serhan CN, Fredman G, Yang R, Karamnov S, Belayev LS, Bazan NG, Zhu M, Winkler JW, Petasis NA. Novel proresolving aspirin-Triggered DHA pathway. Chem Biol 2011; 18: 976-987.
39. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
40. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-411.
41. Basu S, Dittel BN. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 2011; 51: 26-38.
42. Zurier RB, Sun YP, George KL, Stebulis JA, Rossetti RG, Skulas A, Judge E, Serhan CN. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and antiinflammatory eicosanoid, lipoxin A4. FASEB J 2009; 23: 1503-1509.
43. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008; 153: 319-334.
44. Burstein S. Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials. AAPS J 2005; 7: E143-E148.
45. Wenzel SE, Kamada AK. Zileuton: The first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother 1996; 30: 858-864.
46. Rao NL, Dunford PJ, Xue X, Jiang X, Lundeen KA, Coles F, Riley JP, Williams KN, Grice CA, Edwards JP, et al. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther 2007; 321: 1154-1160.
47. Rao NL, Riley JP, Banie H, Xue X, Sun B, Crawford S, Lundeen KA, Yu F, Karlsson L, Fourie AM, et al. Leukotriene A(4) hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2010; 181: 899-907.
48. Springman E, Pugh M, Bhatt L, Grosswald R, Philpot EA, Phase I. Study of CTX-4430, a potential new oral treatment for pulmonary diseases with high medical need [abstract]. Am J Respir Crit Care Med 2014; 189: A1316.
49. Konstan MW, Döring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton A; Investigators and Coordinators of BI Trial 543.45. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 2014; 13: 148-155.
50. Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease? Inflamm Res 2007; 56: 221-227.
51. Kushwah R, Gagnon S, Sweezey NB. Intrinsic predisposition of näive cystic fibrosis T cells to differentiate towards a Th17 phenotype. Respir Res 2013; 14: 138.
52. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011; 184: 252-258.
53. Brodlie M, McKean MC, Johnson GE, Anderson AE, Hilkens CMU, Fisher AJ, Corris PA, Lordan JL, Ward C. Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease. Eur Respir J 2011; 37: 1378-1385.
54. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013; 72: Ii116-ii123.
55. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-1199.
56. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, et al.; Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61: 1693-1700.
57. Dö ring G, Bragonzi A, Paroni M, Aktürk FF, Cigana C, Schmidt A, Gilpin D, Heyder S, Born T, Smaczny C, et al. BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 2014; 13: 156-163.
58. Bonfield TL, Hodges CA, Cotton CU, Drumm ML. Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection. J Leukoc Biol 2012; 92: 1111-1122.
59. van Heeckeren AM, Schluchter M, Xue L, Alvarez J, Freedman S, St George J, Davis PB. Nutritional effects on host response to lung infections with mucoid Pseudomonas aeruginosa in mice. Infect Immun 2004; 72: 1479-1486.
60. van Heeckeren AM, Schluchter MD, Drumm ML, Davis PB. Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 2004; 287: L944-L952.
61. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM; AREST CF Investigators. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368: 1963-1970.
62. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-854.
63. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl MEB, Konstan MW; Pulmozyme Early Intervention Trial Study Group. A two-year randomized, placebocontrolled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-820.
64. VanDevanter DR, Konstan MW. Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clin Investig (Lond) 2012; 2: 163-175.
65. Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL; CF2110399 Investigators. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros 2013; 12: 241-248.
66. Horsley AR., Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, Bell NJ, Rainer M, Mt-Isa S, Voase N, et al. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 2013; 68: 532-539.
67. Vandevanter DR, Yegin A, Morgan WJ, Millar SJ, Pasta DJ, Konstan MW. Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. J Cyst Fibros 2011; 10: 453-459.
68. Block JK, Vandemheen KL, Tullis E, Fergusson D, Doucette S, Haase D, Berthiaume Y, Brown N, Wilcox P, Bye P, et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax 2006; 61: 969-974.
69. Konstan MW, Wagener JS, Yegin A, Millar SJ, Pasta DJ, VanDevanter DR. Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. J Cyst Fibros 2010; 9: 332-338.
70. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Effect of pulmonary exacerbations on long-Term lung function decline in cystic fibrosis. Eur Respir J 2012; 40: 61-66.
71. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-632.
72. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 393-400.